Clinical trials recruiting in Mendoza, Argentina

Phase breakdown

Conditions recruiting in Mendoza, Argentina

Recruiting trials in Mendoza, Argentina

• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
  NCT07525375 · Phase: Phase 2 · Ages: 4 Years to 11 Years · Sex: All (male and female)
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07196748 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
  NCT06664619 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
  NCT07286175 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Schizophrenia
  NCT07410507 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female)
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
  NCT07577843 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07577856 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
  NCT07241390 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  NCT06841354 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
  NCT07646587 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
  NCT07140913 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
  NCT06951698 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
  NCT05562466 · Phase: Phase 3 · Ages: 6 Years to 11 Years · Sex: All (male and female)
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
  NCT07359846 · Phase: Phase 3 · Ages: 12 Years to 80 Years · Sex: All (male and female)
• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
  NCT07082738 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
  NCT06023589 · Phase: Phase 3 · Ages: 5 Years to 11 Years · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
  NCT06878261 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
  NCT07363694 · Phase: Phase 2, Phase 3 · Ages: 35 Years to 80 Years · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
  NCT06977581 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery.
  NCT07388108 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
  NCT07168876 · Phase: Not specified · Ages: 45 Years to 75 Years · Sex: All (male and female)
• Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
  NCT06932263 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System
  NCT03206814 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
  NCT05219617 · Phase: Phase 3 · Ages: 4 Years to 55 Years · Sex: All (male and female)
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
  NCT07415044 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  NCT07116967 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female)
• Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
  NCT07444567 · Phase: Phase 3 · Ages: 6 Years and older · Sex: All (male and female)
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
  NCT07177352 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
  NCT07069829 · Phase: Not specified · Ages: 30 Years to 80 Years · Sex: All (male and female)
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  NCT06136624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
  NCT05303064 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female)
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
  NCT06808984 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
  NCT07301736 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Mendoza, Argentina?

47 recruiting trials have at least one study site in Mendoza, Argentina.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.